Liver health may change how cancer drug works
NCT ID NCT07102095
First seen Feb 14, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study looked at how moderate liver problems affect the way the body handles a new cancer medicine called sevabertinib. About 20 people (10 with liver impairment and 10 healthy) took a single dose and had their blood levels measured. The goal is to help doctors decide the right dose for cancer patients who also have liver disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami - Oncology
Miami, Florida, 33014, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
Conditions
Explore the condition pages connected to this study.